Eleventa, a portfolio company owned by Maxwell Biotech Venture Fund (MBVF) in association with its development partner Oxagen Ltd., has finalized patient enrollment for its Phase 3 Timapiprant clinical trial.
The Phase 3 trial will assess the ability of Timapiprant to treat adults with atopic eosinophilic asthma as well as the drug's safety and tolerability. The trial will include 212 patients and will be randomized, double-blind and conducted in 21 different centers in Russia.
"Timapiprant is intended to reduce airway inflammation and improve control in patients with chronic eosinophilic airways disease, and so reduce dependence on inhaled corticosteroids," Oxagen Ltd. Executive Chairman Tim Edwards said. "A positive trial outcome in Phase 3 trial will further highlight the potential of Timapiprant where new therapies are needed urgently."
Each patient will be administered with Timapiprant or a placebo at a dose of 50 mg. once a day during a 12-week span.
"Eleventa's Timapiprant is effective single systemic therapy for asthma and co-morbid allergies," MBVF managing partner Dmitry Popov said. "Its persistent anti-allergic effects and desensitization may halt the disease progression and provide the improved asthma control in millions of patients."